Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827372 · ClinicalTrials.gov registry record · Phase 2
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
A Phase 2 study of Lymphedema, sponsored by Kathy Miller.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00827372: Completed Phase 2 study of Lymphedema, sponsored by Kathy Miller.
NCT00827372 is a Phase 2 study of Lymphedema that has completed, run by Kathy Miller. The registered enrollment target is 10 participants, below the 9,299-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00827372, a Phase 2 study of Lymphedema, has completed, sponsored by Kathy Miller.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The major purpose of this study is to determine if a new drug called pazopanib decreases lymphedema in subjects previously treated for cancer. Lymphedema, or swelling of the arm, is a result of damage to the lymphatic vessels in the arm during surgery and/or radiation. The damaged vessels can not adequately drain fluid from the arm, resulting in increased pressure and swelling. Pazopanib has not previously been studied as a treatment for lymphedema.
Primary Outcome
The primary endpoint will be change in excess arm volume (affected arm volume minus unaffected arm volume) compared to baseline. This will be done at Cycle 2 (29 days) and Cycle 6 (174 days).
Conditions Studied
Interventions
- DRUG Pazopanib
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00827372 record still lists
NCT00827372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 9,299-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 1 intervention - of which Pazopanib is the first listed.
NCT00827372 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00827372 about?
NCT00827372 is a clinical study titled "A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer". The major purpose of this study is to determine if a new drug called pazopanib decreases lymphedema in subjects previously treated for cancer. Lymphedema, or swelling of the arm, is a result of damage to the lymphatic vessels in the arm during surgery and/or radiation. The damaged vessels can not ad...
What is the current status of trial NCT00827372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-01. Estimated completion is 2010-07.
What conditions does trial NCT00827372 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT00827372?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00827372?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00827372 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00827372's enrollment target sits among peer trials
10 33rd of 34 higher than 2 of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
COMPLETED · Phase 2
-
Pycnogenol for the Treatment of Lymphedema
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia